Published in Drug Metab Dispos on August 25, 2014
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors | NCT01273168
Genetic polymorphisms of CYP2D6*10 and the effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in infertile men with idiopathic oligozoospermia. J Zhejiang Univ Sci B (2015) 0.84
The effects of endoxifen and other major metabolites of tamoxifen on the sulfation of estradiol catalyzed by human cytosolic sulfotransferases hSULT1E1 and hSULT1A1*1. Drug Metab Dispos (2015) 0.75
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Assay of proteins in the presence of interfering materials. Anal Biochem (1976) 17.90
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 4.03
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol (1977) 3.03
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Human sulfotransferases and their role in chemical metabolism. Toxicol Sci (2005) 2.27
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst (2003) 2.25
Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab (1997) 1.96
Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos (2002) 1.92
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Separation of steroid sulfokinases. J Biol Chem (1958) 1.83
Hydroxylated polychlorinated biphenyls are substrates and inhibitors of human hydroxysteroid sulfotransferase SULT2A1. Chem Res Toxicol (2006) 1.58
Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res (1996) 1.55
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem (2003) 1.49
Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst (1999) 1.47
Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie". Drug Metab Dispos (2009) 1.38
Synthesis and protection of aryl sulfates using the 2,2,2-trichloroethyl moiety. Org Lett (2004) 1.38
Purification and characterization of human liver dehydroepiandrosterone sulphotransferase. Biochem J (1989) 1.36
Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res (1991) 1.36
Pharmacogenomics of tamoxifen therapy. Clin Chem (2009) 1.31
CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res (1997) 1.20
Regulation of the adrenal androgen biosynthesis. J Steroid Biochem Mol Biol (2007) 1.17
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids (2007) 1.17
Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis (2000) 1.14
Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos (2005) 1.05
Mutational analysis of human hydroxysteroid sulfotransferase SULT2B1 isoforms reveals that exon 1B of the SULT2B1 gene produces cholesterol sulfotransferase, whereas exon 1A yields pregnenolone sulfotransferase. J Biol Chem (2002) 1.03
The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer (2010) 0.94
Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res (1996) 0.93
Selective role of sulfotransferase 2A1 (SULT2A1) in the N-sulfoconjugation of quinolone drugs in humans. Drug Metab Dispos (2009) 0.92
Pentachlorophenol and other chlorinated phenols are substrates for human hydroxysteroid sulfotransferase hSULT2A1. Chem Res Toxicol (2008) 0.92
Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J Natl Cancer Inst (2004) 0.92
Substrate inhibition in human hydroxysteroid sulfotransferase SULT2A1: studies on the formation of catalytically non-productive enzyme complexes. Arch Biochem Biophys (2010) 0.91
Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. Mol Cell Endocrinol (2013) 0.90
Bioactivation of Selective Estrogen Receptor Modulators (SERMs). Chem Res Toxicol (2006) 0.90
Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem Res Toxicol (1999) 0.89
Assay of purified aryl sulfotransferase suitable for reactions yielding unstable sulfuric acid esters. Anal Biochem (1989) 0.88
Regulation of sulphotransferase expression in the endometrium during the menstrual cycle, by oral contraceptives and during early pregnancy. Mol Hum Reprod (1999) 0.88
Introduction of 2,2,2-trichloroethyl-protected sulfates into monosaccharides with a sulfuryl imidazolium salt and application to the synthesis of sulfated carbohydrates. Angew Chem Int Ed Engl (2006) 0.88
Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst (1993) 0.88
Interactions of cytosolic sulfotransferases with xenobiotics. Drug Metab Rev (2013) 0.87
Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis (1999) 0.87
alpha-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res (1994) 0.85
Roles of electrophilic sulfuric acid ester metabolites in mutagenesis and carcinogenesis by some polynuclear aromatic hydrocarbons. Chem Biol Interact (1994) 0.85
Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res (1998) 0.85
Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis (1998) 0.85
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat (2012) 0.85
Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos (2010) 0.84
Hydroxysteroid sulfotransferase. Methods Enzymol (1981) 0.84
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat (2013) 0.84
Metabolism of tamoxifen by rat liver microsomes: formation of the N-oxide, a new metabolite. Biochem Pharmacol (1980) 0.82
Interactions of the stereoisomers of alpha-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa. Drug Metab Dispos (2004) 0.80
Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol Cell Endocrinol (1982) 0.80
Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab Dispos (1993) 0.79
Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. Toxicology (2008) 0.79
Tamoxifen-DNA adduct formation in monkey and human reproductive organs. Carcinogenesis (2014) 0.78